Satellite Companies

We expand the reach and potential of our RNA-based therapeutics into disease areas that are outside of our core focus areas through our drug discovery and development satellite company partners. Our satellite company partners have resources and expertise that are focused in a particular disease area and share the common goal of advancing our drugs. In these partnerships, we typically own equity in the company, often as part of the licensing agreement, and we also retain the potential to earn milestone payments and royalties. Our satellite company strategy allows us to create and support a much broader product pipeline than we could develop on our own.

In addition, we have satellite company partnerships focused on developing and advancing certain RNA-based therapeutic technologies. These partnerships take advantage of our dominant intellectual property estate and leverage our own investments in our core technologies. Typically a cross license between us and our partner allows us to participate in newly emerging approaches to RNA-based therapeutics that augment our active programs in these areas.

Regulus

We and our partner, Alnylam, established and are joint owners of Regulus Therapeutics, a company that is focused on the discovery, development and commercialization of microRNA-based therapeutics.

Learn More